India’s private tertiary healthcare industry is undergoing a structural expansion. Rising incomes, growing insurance penetration, medical tourism, and a widening gap between demand and quality bed capacity are creating a powerful multi-year opportunity for large, branded hospital chains.
Among India’s private hospital groups, Global Health Ltd., which operates under the “Medanta” brand, has built a strong super-specialty franchise across North and East India. What makes the company interesting is its combination of high-acuity clinical specialties (cardiac sciences, oncology, neurosciences, transplants), a disciplined greenfield expansion strategy and a fast-improving profitability profile at its newer hospitals.
But does Global Health Ltd. offer a compelling case for long-term investors? Let’s delve deeper.
Stock overview
| Ticker | MEDANTA |
| Industry/Sector | Hospital & Healthcare |
| CMP | 1410.00 |
| Market Cap (₹ Cr.) | 37,911 |
| P/E | 69.09 (Vs Industry P/E of 64.62) |
| 52 W High/Low | 1491.00 / 956.00 |
| EPS (TTM) | 20.54 |
| Dividend Yield | 0.00% |
About Global Health Ltd.
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, marketed under the “Medanta” brand. The company operates 6 hospitals-Gurugram, Indore, Ranchi, Lucknow, Patna and Noida-spanning an installed capacity of 3,737 beds as of Q1 FY27 and offers services across 30+ medical specialties supported by 2,000+ doctors.
The company’s key clinical strengths lie in cardiology and cardiac sciences, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. Heart, cancer, digestive, neuro and urology specialties together contributed ~64.6% of Q1 FY27 revenue. Medanta also has a growing international patient base and an expanding OPD pharmacy and retail diagnostics footprint, particularly across Uttar Pradesh and Bihar.
Key business segments
Global Health Ltd. operates primarily in the following key business segments:
- Hospitals & Healthcare Services: Multi-specialty healthcare and patient treatment services.
- Diagnostics: Pathology, radiology and other diagnostic testing services.
- Pharmaceuticals: Manufacturing and distribution of prescription and healthcare products.
- Health Insurance: Insurance solutions covering medical and healthcare expenses.
- Digital Health: Telemedicine, online consultations and technology-enabled healthcare services.
- Medical Devices & Equipment: Manufacturing and distribution of medical equipment, devices and consumables.
Primary growth factors for Global Health Ltd.
Global Health Ltd. key growth drivers:
- Growing Healthcare Demand: Rising healthcare needs driven by ageing populations and lifestyle-related diseases.
- Healthcare Infrastructure Expansion: Increasing investments in hospitals, diagnostics and healthcare facilities.
- Rising Insurance Penetration: Greater health insurance coverage improving access and affordability.
- Preventive & Diagnostic Care: Growing focus on early diagnosis and preventive healthcare.
- Digital Healthcare Adoption: Technology, telemedicine and AI improving healthcare accessibility and efficiency.
- Expansion into Smaller Cities: Rising incomes and healthcare infrastructure creating opportunities in Tier-II and Tier-III cities.
Detailed competition analysis for Global Health Ltd.
Key financial metrics – TTM;
| Company | Sales (₹ Cr.) | EBITDA (₹ Cr.) | EBITDA Margin (%) | PAT (₹ Cr.) | PAT Margin (%) | P/E |
| Global Health Ltd. | 4212.50 | 832.80 | 19.77% | 190.80 | 4.53% | 69.09 |
| Narayana Hrudayalaya Ltd. | 9072.40 | 1749.42 | 19.28% | 828.72 | 9.13% | 44.61 |
| Dr. Lal PathLabs Ltd. | 2890.80 | 837.70 | 28.98 | 546.30 | 18.90% | 57.97 |
| Aster DM Quality Care Ltd. | 4876.03 | 957.99 | 19.65% | 402.49 | 8.25% | 192.48 |
| Fortis Healthcare Ltd. | 9506.15 | 2131.43 | 22.42% | 1052.40 | 11.07% | 64.23 |
Key insights on Global Health Ltd.
- Diversified platform: Presence across hospitals and allied healthcare services.
- Strong Medanta brand: Established reputation supporting patient trust and premium positioning.
- Expansion-led growth: New hospitals and capacity additions drive revenue growth.
- Specialty focus: High-value specialties support better realisations.
- Structural demand: Rising healthcare needs and insurance penetration support growth.
- Operating leverage: Higher utilisation can improve profitability.
- Regional concentration: Strong North India presence creates geographic concentration risk.
Recent financial performance of Global Health Ltd. for Q1 FY27
| Metric | Q1 FY26 | Q4 FY26 | Q1 FY27 | QoQ Growth (%) | YoY Growth (%) |
| Sales (₹ Cr.) | 1030.84 | 1159.05 | 1304.05 | 12.51% | 26.50% |
| EBITDA (₹ Cr.) | 226.99 | 243.76 | 286.75 | 17.64% | 26.33% |
| EBITDA Margin (%) | 22.02% | 21.03% | 21.99% | 96 bps | -3 bps |
| PAT (₹ Cr.) | 158.98 | 141.65 | 157.25 | 11.01% | -1.09% |
| PAT Margin (%) | 15.42% | 12.22% | 12.06% | -16 bps | -336 bps |
| Adjusted EPS (₹) | 5.92 | 5.36 | 5.91 | 10.26% | -0.17% |
Global Health Ltd. financial update (Q1 FY27)
Financial performance
- Revenue grew 26.5% YoY to ₹1,304 crore. in Q1FY27, driven by robust patient volume growth and continued ramp-up of developing hospitals, particularly Noida.
- EBITDA grew 26.3% YoY to ₹287 crore in Q1FY27, though the EBITDA margin contracted by 3 bps YoY to 22%, reflecting the drag from the ongoing Noida ramp-up.
- In-patient volumes rose 27.7% YoY to 60.2k, while out-patient footfalls rose 34.5% YoY to 1.1 million, driving 21.1% growth in occupied bed days.
- ARPOB improved 5.5% YoY to ₹70,244, helped by a favourable case mix and shorter average length of stay (2.87 days vs 3.03 days).
Business highlights
- Cluster 2 hospitals (Lucknow, Patna, Noida) grew revenue 54.8% YoY to ₹5.0 billion, now contributing 39% of total revenue.
- Noida’s EBITDA loss narrowed sharply to ₹49m from ₹236m in Q4FY26, signalling a faster-than-expected path to profitability.
- 70+ doctors, including 50+ senior clinicians, were onboarded during the quarter, with negligible attrition at senior clinical levels.
- The Guwahati greenfield project was expanded to a 650-bed super-specialty hospital with a revised project cost of ~₹9.7 billion.
- Medanta added 72 beds in Q1FY27 (51 at Noida, 21 at Lucknow), taking installed capacity to 3,737 beds, and plans to add a total of 490 beds in FY27.
Outlook
- Medanta’s expansion remains on track, with Guwahati scaled to 650 beds at ₹970 crore and South Delhi construction underway.
- Bed capacity growth remains strong, with 72 beds added in 1QFY27 and further additions planned across Noida, Lucknow and new greenfield sites.
- ₹48.5bn five-year capex will be funded through internal accruals, surplus cash and moderate leverage, supporting disciplined, largely self-funded growth.
- Total project capex of ₹48.5 billion is planned over the next five years (including ₹6.0 billion of maintenance capex), to be funded through internal accruals, surplus cash and comfortable financial leverage.
- Construction is underway at the South Delhi hospital (DLF partnership), while the 750-bed Pitampura hospital remains at the planning stage under an O&M model.
Recent Updates on Global Health Ltd.
- Capacity Expansion: Guwahati hospital project expanded to 650 beds at a revised cost of ₹970 crore.
- AGM: Annual General Meeting scheduled for September 16, 2026.
- Institutional Ownership: DII holding rose from 14.8% (Mar’26) to 16.9% (Jun’26); FII holding fell from 10.2% to 9.5% over the same period, while promoter holding remained steady at 33.0%.
- Bulk/Block Deals: HDFC Mutual Fund purchased 1,000,000 shares each in May ’26 and Jun’26 (at ₹1,225 and ₹1,300 respectively) as Sunil Sachdeva sold matching blocks.
Company valuation insights – Global Health Ltd.
Global Health is currently trading at a 12-month forward EV/EBITDA of 28x. The stock has delivered a relatively modest 2.3% return over the last one year, outperforming the Nifty 50’s -3.3% return, leaving scope for further upside as earnings growth and capacity expansion gain momentum.
The investment thesis is supported by Global Health’s strong Medanta brand, leadership in tertiary and quaternary healthcare, and presence across high-value medical specialties, supporting strong patient realisations and profitability. Continued hospital expansion, rising bed capacity and improving utilisation provide a visible pathway for revenue and earnings growth, while rising healthcare demand, increasing insurance penetration and expansion into new geographies offer long-term structural tailwinds.
We value Global Health at 28x its 12-month forward EV/EBITDA, arriving at a 12-month target price of ₹1,750, implying an upside potential of 24% from current levels. While the stock trades at a premium valuation, we believe this is justified by its strong brand equity, specialty-led healthcare model, expansion opportunities and potential operating leverage. For the near term, we maintain a 3-month technical target of ₹1,495, implying a 6% upside potential from current levels.
Major risk factors for Global Health Ltd.
- Cluster Concentration: 61% of revenue still comes from three mature hospitals; Gurgaon faces a structural cap on bed additions.
- Execution Risk on Greenfield Pipeline: ₹48.5 billion of planned capex across Guwahati, Mumbai, South Delhi, Pitampura and Varanasi carries execution and funding risk, even though management expects internal accruals and debt to suffice.
- Regulatory & Pricing Risk: Tertiary healthcare pricing and insurance-linked reimbursement policies can affect ARPOB and margins.
- Talent Retention: Continued growth depends on the company’s ability to retain and attract senior clinicians amid intense competition for medical talent.
- New Hospital Gestation: While Noida’s ramp-up has been faster than expected, greenfield hospitals typically carry multi-year gestation periods before turning profitable.
Technical analysis of Global Health Ltd. share
Global Health remains in a broader uptrend, with the stock trading above all its key EMAs, indicating that the underlying trend remains positive. While short-term momentum has moderated, the overall technical structure remains constructive. A decisive breakout above ₹1,495 could trigger renewed buying momentum and potentially pave the way towards ₹1,750, in line with our 12-month fundamental target.
Momentum indicators indicate a stable setup with potential for further strengthening. The MACD at 19.43 remains in positive territory but is currently just below its signal line; a bullish crossover could reinforce the ongoing uptrend. The RSI at 51.82 indicates decent buying strength without approaching overbought levels, leaving room for further upside. The 21-day and 55-day Relative RSI readings of 0.03 and 0.13, respectively, also indicate continued outperformance against the benchmark.
Trend strength remains relatively weak, with the ADX at 19.55 suggesting a range-bound market. However, a bullish MACD crossover, followed by a decisive breakout above ₹1,495, could strengthen the trend and attract fresh buying interest. On the downside, ₹1,290 remains the key support and stop-loss level for the bullish view.
- RSI: 51.82 (Decent buying interest)
- ADX: 19.55 (Range-bound; MACD crossover could strengthen the trend)
- MACD: 19.43 (Positive; bullish crossover awaited)
- Resistance: ₹1,495
- Support: ₹1,290
Global Health Ltd. stock recommendation
Current Stance: Buy, with a 3-month target price of ₹1,495 (6% upside) and a 12-month target price of ₹1,750 (24% upside), based on a valuation of 28x 12-month forward EV/EBITDA.
Why buy now?
Strong Medanta brand and established positioning in tertiary and quaternary healthcare.
Continued hospital expansion and bed-capacity additions provide visibility for long-term revenue growth.
Rising healthcare demand, increasing insurance penetration and growing demand for specialised treatments support structural growth.
Presence across high-value medical specialties supports strong patient realisations and profitability.
Improving utilisation of existing and new capacities offers potential for operating leverage and margin expansion.
Portfolio fit
Global Health offers exposure to India's structural healthcare growth story, supported by rising healthcare expenditure, increasing insurance penetration and growing demand for specialised medical services. Its strong Medanta brand, specialty-led healthcare model and ongoing capacity expansion provide a visible pathway for sustained revenue and earnings growth. With opportunities to improve utilisation, scale its presence across new geographies and benefit from operating leverage, Global Health represents an attractive addition for investors seeking exposure to the long-term growth of India's organised healthcare sector.If you found this helpful and want regular stock trade calls, check out my community on StockGro here: https://app.stockgro.club/ui/social/tradeViews/groupFeed/07a7b961-b8ca-42ce-baf3-a9eec781b6ebGlobal Health Ltd.: Budget 2026-27 opportunities
- Higher Healthcare Spending: Increased government healthcare allocation supports long-term sector growth and healthcare utilisation.
- Insurance-Led Access: Higher PM-JAY allocation can improve access to quality hospital care and expand the patient pool.
- Healthcare Infrastructure Push: Increased spending on hospitals, critical-care facilities and advanced medical infrastructure supports sector expansion.
- Medical Value Tourism: The proposed development of regional medical hubs could support growth in domestic and international patient inflows.
- Digital Healthcare: Higher allocation towards digital health can improve efficiency, interoperability and technology adoption across healthcare providers.
Final thoughts
Global Health Ltd. (Medanta) stands at an important inflection point, transitioning from a concentrated three-hospital franchise into a pan-India super-specialty network. Its established clinical brand, disciplined and increasingly efficient greenfield expansion playbook, and exposure to India’s structural under-penetration in tertiary healthcare provide a compelling long-term growth opportunity.
For investors seeking exposure to India’s premium private healthcare consumption story, Medanta offers a differentiated, high-acuity growth play with a long runway of bed capacity additions. However, the key is to look beyond headline revenue growth and track occupancy, ARPOB, new-hospital breakeven timelines and capex discipline, given the stock’s already-elevated valuation multiples.
The long-term thesis is therefore not simply “India needs more hospital beds”, it is “Medanta can keep converting its greenfield pipeline into profitable capacity faster than the market currently gives it credit for.”
